16 / 115
M
artits
AM
et
al
.
294
R
ev
A
ssoc
M
ed
B
ras
2014; 60(4):286-294
31. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods
for the estimation of free testosterone in serum. J. Clin Endocrinol Metab
1999;84:3666-72.
32.
Morley JE, Perry HM 3
rd
, Patrick P, Dollbaum CM, Kells JM. Validation of
salivary testosterone as a screening test for male hypogonadism. aging Male
2006;9:65-9.
33. Thienpont LM, Van Uytfanghe K, Blincko S, Ramsay CS, Xie H, Doss RC, et al.
State-of-the-art of serum testosterone measurement by isotope dilution-liquid
chromatography-tandemmass spectrometry. Clin Chem 2008;54:1290-7.
34. DeRonde W, van der Schouw YT, Pols HAP, Gooren LJG, Muller M, Grobbee
DE, et al. Calculation of bioavailable and free testosterone inmen: a comparison
of 5 published algorithms. Clinical Chemistry 2006;52:1777-84.
35.
Ly LP, Handelsman DJ. Empirical estimation of free testosterone from
testosterone and sex-hormone binding globulin immunoassays. Eur J
Endocrinology 2005;105:471-8.
36.
Rosner W, Vesper H. Toward Excellence in testosterone Testing: A Consensus
Statement. J Clin Endocrinol Metab2010;95:4542-8.
37. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse
events associated with testosterone replacement in middle- aged and older
men: a meta-analysis of randomized, placebo-controlled trials. J Geront A
BiolSci Med Sci 2005;60:1451-7.
38.
Bhasin S, Cunnigham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swedloff
RS, et al. testosterone therapy in men with androgen deficiency syndromes:
an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab
2010; 95:2536-59.
39. Wang C, Nieschlag E, Swerdloff R, Behre HM, HellstromWJ, Gooren LJ, et
al. Investigation, treatement, and monitoring of late-onset hypogonadism
in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl
2009;30:1-9.
40.
Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and
body mass index modulate the safety of long- term intramuscular testosterone
undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab
2007;92:3844-53.
41.
Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM,
Bosch JL, et al. Effect of testosterone supplementation on functional mobility,
cognition, and other parameters in older men: a randomized controlled
trial. JAMA 2008;299: 39-52.
42.
Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and
recommendations for monitoring. N Engl J Med 2004;350:482-92.
43.
Merza Z, Blumsohn A, Mah PM, Meads DM, McKenna SP, Wylie K, et al.
Double blind placebo controlled study of testosterone patch therapy on
bone turnover in men with borderline hypogonadism. Int J Androl
2006;29:381-91.
44. Amory JK, Watts NB, Easley KA, Sutton PR, Anawalt BD, Matsumoto AM,
et al. Exogenous testosterone or testosterone with finasteride increases bone
mineral density in older men with low serum testosterone. J Clin Endocrinol
Metab 2004; 89:503-10.
45.
Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, et al. Effect
of testosterone treatment on bone mineral density in men over 65 years of
age. J Clin Endocrinol Metab 1999; 84:1966-72.
46.
Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect
of testosterone replacement therapy on prostate tissue in men with late
onset hypogonadism: a randomized controlled trial. JAMA 2006;296:2351-
61.
47.
Buvat J, Maggi M, Guay A, Torres LO. testosterone deficiency in men:
systematic review and standard operating procedures for diagnosis and
treatment. J Sex Med 2013;10:245-84.
SCIELO.indb 294
8/1/14 2:28 PM